Sanofi – Top line data of Oral Eliglustat Tartrate in Gaucher Disease- Positive but not Enough

Date: 2015-07

Sanofi reported positive Phase 3 top line data on Eliglustat Tartrate – a twice daily capsule for Gaucher disease. SAN continues to progress well in executing its pipeline, but we are worried on whether it would be able to meet its mid term guidance of sales growth (5% over 2012-15) as most of the immediate growth opportunities (Aubagio, Lemtrada, Eliglustat) have limited sales potential. Eliglustat Tartrate has demonstrated a 30% decrease in spleen volume compared to placebo at nine months in treatment na茂ve type-1 Gaucher鈥檚 Disease patients. The efficacy is much lower than currently approved IV Enzyme replacement Therapy (~40-60%), but better than its direct competitior- Zavesca (Oral substrate reduction therapy from Actelion- 19% reduction in spleen volume). On safety front, no major serious adverse events are reported. Safety is comparable to ERT鈥檚 and better than Zavesca. Zavesca from Actelion is a thrice daily capsule and has reported $75m sales in 2011


Contact With Us
Join templatemonster at google+
Customized Research
Request Sample